淘寶店鋪小賣家如何做到差異化營銷_第1頁
淘寶店鋪小賣家如何做到差異化營銷_第2頁
淘寶店鋪小賣家如何做到差異化營銷_第3頁
淘寶店鋪小賣家如何做到差異化營銷_第4頁
淘寶店鋪小賣家如何做到差異化營銷_第5頁
已閱讀5頁,還剩47頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領

文檔簡介

1、Drug Treatment of Metastatic Breast CancerFDA Approval OverviewPatricia Cortazar, MD微快車微信營銷 weikuaiche .Drugs approved for Metastatic Breast CancerMethotrexate1953Cyclophosphamide1959Thiotepa1959Vinblastine19615-Fluorouracil1962Doxorubicin1974.Paclitaxel1994Docetaxel1996Trastuzumab 1998Capecitabine1

2、998Capecitabine + Docetaxel2001Abraxane2005Lapatinib2006Ixabepilone2007Drugs approved in 2nd-3rd line Metastatic Breast Cancer.PaclitaxelTAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemo

3、therapy. Prior therapy should have included an anthracycline unless clinically contraindicated . Paclitaxel mg/m2 3-hour infusionTAXOL Study Design Paclitaxel 175 mg/m23-hour infusion 471Patients who failed one or two regimensof chemotherapy67% previous anthracyclines.TAXOL Efficacy ResultsFull Appr

4、ovalPaclitaxel 175235Paclitaxel 135236Response (months)28%22% P-value (log rank)p=0.135TTP median (months)4.23.0 P-value (log rank)p=0.027Survival (months)11.710.5 P-value (log rank)p=0.321.DocetaxelTAXOTERE for Injection indicated for the treatment of patients with locally advanced or metastatic br

5、east cancer after failure of prior chemotherapy.DocetaxelAccelerated Approval 19963 Phase II studies in total 134 patientsDose 100 mg/m2 q 3 weeksEndpoint: Overall RR 41% (95% CI: 33-49)PMC: Submit data from controlled clinical studies (TAX311, TAX304). Mytomicin 12 mg/m2 Q 6 weeks Vinblastine 6 mg/

6、m2 Q 3 weeksTAX304 Study Design Docetaxel 100 mg/m2Q 3 weeks 392Patients with Prior anthracyclineregimens.TAX304 Efficacy ResultsFull ApprovalDocetaxel203Myt +Vinblastine189TTP (months)4.32.5 Risk Ratio 95% CI (RR)0.750.61-0.94 P-value (log rank)p=0.01Survival (months)11.48.7 Risk Ratio* 95% CI (RR)

7、0.730.58-0.93 P-value (log rank)p=0.01.TrastuzumabHerceptin is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease. .Trastuzumab 4 mg/kg loading dose2 mg/kg wk

8、ly maintenanceHerceptin MBC Study Design222Patients with MBCHER2 overexpression2+3+1 or 2 prior CT for MBCAnthracycline and Taxane.Herceptin monotherapy Full ApprovalResponse Rate14%CR2%PR12%Response Duration median (months)9Survival median (months)12.8.CapecitabineXeloda is indicated for the treatm

9、ent of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin

10、or doxorubicin equivalents.Capecitabine monotherapy Accelerated ApprovalPatients resistant to paclitaxel and anthracycline43CR0PR11Response Rate95% CI25.6%(13.5, 41.2)Response Duration median (days)Range154(63-233).CapecitabineXeloda is indicated in combinationwith Taxotere (docetaxel) for the treat

11、ment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.Docetaxel 100 mg/m2Q 3 weeksStudy Design Capecitabine 1250 mg/m2 twice daily for 14 days Docetaxel 75 mg/m2 Q 3 weeks511metastaticbreast cancer resistant to Anthracycline30

12、% 1st line.Capecitabine Efficacy ResultsFull ApprovalCapeciabine + DocetaxelDocetaxelTTP (median days)186128 95% CI(165-198)(105-136) Hazard Ratio0.643 P-value (log rank)p=0.01Survival (median days)442352 95% CI(375-497)(298-387) Hazard Ratio0.775 P-value (log rank)0.0126.Overall Survivalmedian days

13、Docetaxel - 352Capecitabine + Doc - 442 Log rank p=0.0126.LapatinibTYKERB in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over-express HER2 (ErbB2) who have received prior therapy including an anthracycline, a taxane and trastuzum

14、ab. Capecitabine 2500 mg/m2 daily for 14 days Study DesignLapatinib 1250 mg/m2 continuouslyCapecitabine 2000 mg/m2 daily for 14 days 399Locally advancedor metastaticbreast cancerHER2+ prior anthracycline,Taxane andHerceptin.Lapatinib Efficacy ResultsFull ApprovalIndependent radiology ReviewInvestiga

15、torLap +CapCapLap +CapCapTTP # events82102121126Median (weeks)27.118.623.918.3Hazard ratio 95% CI0.57(0.43, 0.77)0.72(0.56, 0.92)P-value0.000130.00762ORR %23.713.931.817.4.Efficacy of Combination Therapy:Kaplan-Meier Curves of TTPLapatinib + Capecitabine -Capecitabine -p= 0.00013.IxabepiloneCombinat

16、ion Therapy:Ixempra is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant or for whom further anthracycline therapy is contraindicate

17、d. . Capecitabine 1250 mg/m2 BID Days 1 to 14 q 21 daysStudy Design Ixabepilone 40 mg/m2 Days 1 q 21 days Capecitabine1000 mg/m2 BID Days 1 to 14 q 21 days752Resistant to Taxane andanthracycline.Ixabepilone Efficacy ResultsFull ApprovalIxa + Cape375Capecitabine377PFS (months)5.74.1 Hazard Ratio 95%

18、CI 0.690.58-0.83 P-value (log rank)p 0.0001.Efficacy of Combination Therapy:Kaplan-Meier Curves of PFSlog rank p 0.0001.IxabepiloneMonotherapy:Ixempra is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to

19、 anthracyclines, taxanes, and capecitabine. Single-arm Monotherapy Studies (n=126)Independent radiology ReviewInvestigatorORR (%)12.418.3 95% CI6.9, 19.911.9, 26.1Response DurationMedian (months)6.0 95% CI5.0, 7.6.1st line Metastatic Breast Cancer.Drugs approved in 1st line Metastatic Breast CancerH

20、erceptin + Paclitaxel 1998Gemcitabine + Paclitaxel 2004.TrastuzumabHerceptin in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress HER2 protein and who have not received chemotherapy for their metastatic disease. .Chemotherapy Al

21、oneHerceptin 1st line MBC Study Design Chemotherapy (AC or Paclitaxel) Herceptin loading: 4 mg/kg weekly: 2 mg/kg469Patients with untreated MBCHER2 overexpression2+3+.Survival Time (months)Proportion Alive0510152025300.00.20.40.60.81.0Survival ALL PatientsHerceptin 79%Control 68%P 0.01.Herceptin Ful

22、l ApprovalSurvival All Patients.Time to Progression (Months)Proportion Progression-Free05101520250.00.20.40.60.81.0Time to Progression All PatientsHerceptinControlp 0.001.GemcitabineGemzar in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast can

23、cer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.Paclitaxel175 mg/m2 Days 1 and 8 q 21 daysStudy Design Gemcitabine 1250 mg/m2Days 1 and 8 q 21 days Paclitaxel175 mg/m2Days 1 and 8 q 21 days529Unresectable,locally recurr

24、entor metastaticbreast cancer.SurvivalGemzar/Paclitaxel - 18.6 monthsPaclitaxel - 15.8 monthsLog rank p=0.0489 SURVIVAL.Time to Progression.ENDPOINTS Metastatic Breast Cancer.Survival: Basis of cytotoxic drug approval in 1st line MBCCytotoxic and biologic drugs are toxicSurvival is both a safety and

25、 an efficacy parameterDeaths are caused by toxicity orprogressive disease or both.Efficacy Reasons for using Survival as basis of approval in 1st line MBCEffective drugs prolong life:Doxorubicin based regimens 6 monthsHerceptin 5 monthsDocetaxel 3 months Capecitabine + Docetaxel 3 months .Survival a

26、s a basis of approval: Examples1st Line MBC:Herceptin + PaclitaxelGemcitabine + Paclitaxel2nd Line MBCDocetaxel monoterapy andCapecitabine + Docetaxel after failure of prior chemotherapy.Cross-over therapy confounds survival effect: truth or myth?According to ODAC 6/99: NoNo literature to support th

27、is statementA drug used after tumor progression should have the same effect in both arms, and should not obscure the effect of the drug tested. Examples:Herceptin + chemo better than chemo, in spite of a 65% cross-over rateCamptosar + 5-FU/leucovorin better than 5-FU/leucovorin, in spite of a 40% cross-over rate.SUMMARY.See ODAC transcript for Monday June 7, 1999, posted on the FDA websiteTTP: Not acceptable for traditional ap

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論